SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-016392
Filing Date
2023-05-11
Accepted
2023-05-11 16:15:52
Documents
78
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1369105
2 ex31-1.htm EX-31.1 35259
3 ex32-1.htm EX-32.1 9478
  Complete submission text file 0001493152-23-016392.txt   7686869

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lctx-20230331.xsd EX-101.SCH 53880
5 XBRL CALCULATION FILE lctx-20230331_cal.xml EX-101.CAL 66933
6 XBRL DEFINITION FILE lctx-20230331_def.xml EX-101.DEF 202963
7 XBRL LABEL FILE lctx-20230331_lab.xml EX-101.LAB 408380
8 XBRL PRESENTATION FILE lctx-20230331_pre.xml EX-101.PRE 316299
72 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1557436
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12830 | Film No.: 23911244
SIC: 2836 Biological Products, (No Diagnostic Substances)